General Information of Drug (ID: DM830EN)

Drug Name
NEO-201 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM830EN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SAR408701 DMXGE3O Non-small-cell lung cancer 2C25.Y Phase 3 [3]
Tusamitamab ravtansine DMMPSA1 Non-small-cell lung cancer 2C25 Phase 3 [4]
IDM-2101 DMABRXY Colorectal cancer 2B91.Z Phase 2 [5]
CAP1-6D DMEYIVW Pancreatic cancer 2C10 Phase 2 [6]
Pentacea DMGY5JC Small-cell lung cancer 2C25.Y Phase 2 [7]
GI-6207 DM72O6F Thyroid cancer 2D10 Phase 2 [8]
CeaVac DM6Z9BV Colorectal cancer 2B91.Z Phase 2 [9]
Labetuzumab I-131 DMNO5UE Colorectal cancer 2B91.Z Phase 2 [10]
AVX701 DMOPVIQ Colorectal cancer 2B91.Z Phase 1/2 [11]
CT84.66 DM6078F Breast cancer 2C60-2C65 Phase 1/2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CM24 DM8CROB Aggressive cancer 2A00-2F9Z Phase 1/2 [13]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Biliary glycoprotein 1 (CEACAM1) TTA9CK4 CEAM1_HUMAN Inhibitor [2]
Carcinoembryonic antigen CEA (CD66e) TTY6DTE CEAM5_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03476681) QUILT-3.017: Study of NEO-201 in Solid Tumors. U.S. National Institutes of Health.
2 The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway. Cancer Biother Radiopharm. 2020 Apr;35(3):190-198.
3 ClinicalTrials.gov (NCT02187848) Evaluation of SAR408701 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
4 Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416-425.
5 Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25.
6 Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997 Oct 15;57(20):4570-7.
7 Antibody fragments: Hope and hype. MAbs. 2010 Jan-Feb; 2(1): 77-83.
8 Clinical pipeline report, company report or official report of GlobeImmune.
9 Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol. 1999 Sep;17(9):2889-5.
10 National Cancer Institute Drug Dictionary (drug id 692828).
11 Viral vector-based therapeutic cancer vaccines. Cancer J. 2011 Sep-Oct;17(5):359-71.
12 Technology evaluation: cT84.66, City of Hope. Curr Opin Mol Ther. 2004 Feb;6(1):90-5.
13 Clinical pipeline report, company report or official report of Purple